Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTIFOC0)

DTT Name Immunoglobulin gamma Fc receptor IIIA (FCGR3A)
Synonyms FCGR3A
Gene Name FCGR3A
DTT Type
Clinical trial target
 [1]
Related Disease
Hodgkin lymphoma [ICD-11: 2B30]
Mature T-cell lymphoma [ICD-11: 2A90]
Mycosis fungoides [ICD-11: 2B01]
Lymphoma [ICD-11: 2A80-2A86]
Solid tumour/cancer [ICD-11: 2A00-2F9Z]
Multiple myeloma [ICD-11: 2A83]
BioChemical Class
Immunoglobulin
UniProt ID
FCG3A_HUMAN
TTD ID
T59001
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW
FHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE
EDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN
VSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW
KDHKFKWRKDPQDK
Function
Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.
KEGG Pathway
Phagosome (hsa04145 )
Osteoclast differentiation (hsa04380 )
Neutrophil extracellular trap formation (hsa04613 )
Natural killer cell mediated cytotoxicity (hsa04650 )
Fc gamma R-mediated phagocytosis (hsa04666 )
Leishmaniasis (hsa05140 )
Staphylococcus aureus infection (hsa05150 )
Tuberculosis (hsa05152 )
Systemic lupus erythematosus (hsa05322 )
Reactome Pathway
FCGR activation (R-HSA-2029481 )
Regulation of actin dynamics for phagocytic cup formation (R-HSA-2029482 )
Role of phospholipids in phagocytosis (R-HSA-2029485 )
FCGR3A-mediated IL10 synthesis (R-HSA-9664323 )
FCGR3A-mediated phagocytosis (R-HSA-9664422 )
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell (R-HSA-198933 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
3 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
AFM13 DMN45IC Hodgkin lymphoma 2B30 Phase 2 [2]
AFM24 DMFTZX0 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
RG6296 DMEFUSJ Multiple myeloma 2A83 Phase 1 [3]
------------------------------------------------------------------------------------

References

1 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
2 Clinical pipeline report, company report or official report of Affimed Therapeutics.
3 Clinical pipeline report, company report or official report of Genentech.